ImmunityBio (IBRX) verklagt nach FDA-Warnung zu irreführenden Krebsbehauptungen; Aktien fallen um 21%, Marktwert sinkt um 2 Mrd. USD.

Quelle: PR Newswire
Link: https://www.prnewswire.com/news-releases/ibrx-shareholder-update-immunitybio-ibrx-sued-after-fda-flags-misleading-cancer-claims-shares-plunge-21-2b-market-cap-lost—-hagens-berman-302754913.html